Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives (Q38721253)

5 September 2017

1 reference

title

Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives (English)

1 reference

5 September 2017

1 reference

Michael B Atkins

1

1 reference

5 September 2017

James Larkin

series ordinal

2

1 reference

5 September 2017

language of work or name

English

0 references

publication date

2 February 2016

1 reference

Journal of the National Cancer Institute

5 September 2017

published in

1 reference

5 September 2017

volume

108

1 reference

5 September 2017

issue

6

1 reference

5 September 2017

page(s)

djv414

1 reference

Hallmarks of Cancer: The Next Generation

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Systematic review of medical treatment in melanoma: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Optimal management of metastatic renal cell carcinoma: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Bevacizumab plus ipilimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJV414

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJV414

1 reference

5 September 2017

1 reference